Translational Research refers to a particular type of research primarily aimed to improve human health. This means using basic knowledge in biology, technology, physics (..) for clinical uses.
Ìý
- BASIC overview of the translational path
ACCELERATE Potential | ¹û¶³Ó°Ôº School of Life and Medical Sciences - ¹û¶³Ó°Ôº – ¹û¶³Ó°Ôº. This online course is an introduction to the Translational Research and the Translational Path. Self paced, for ¹û¶³Ó°Ôº staff/studentsÌýand externals.
The Academic Careers Office (ACO) at ¹û¶³Ó°Ôº is part of the Office of the Vice Provost for Health (OVPH). The OVPH's mission is to enhanceÌýexternal relationships in biomedicine with a range of medical research organisations, NHS included. The ACOÌýpromotes, supports and develops many aspects of academicÌýin health related disciplines across ¹û¶³Ó°Ôº. As ¹û¶³Ó°Ôº students and researchers at ¹û¶³Ó°Ôº Queen Square IoN, everyone is welcomed to use this resource.ÌýACCELERATE | ¹û¶³Ó°Ôº School of Life and Medical Sciences - ¹û¶³Ó°Ôº – ¹û¶³Ó°Ôº
- ADVANCED overview of therapeutic development by modality: biologics, gene and cell therapy, devices and diagnostics, regenerative medicine, small molecule and repurposingo
Click on the modality you are interested to explore. Roadmaps:
-ÌýBiologics Translation Roadmap | ¹û¶³Ó°Ôº Therapeutic Innovation Networks - ¹û¶³Ó°Ôº – ¹û¶³Ó°Ôº
-ÌýCell & Gene Therapy Translation Roadmap | ¹û¶³Ó°Ôº Therapeutic Innovation Networks - ¹û¶³Ó°Ôº – ¹û¶³Ó°Ôº
-ÌýDevices Translation Roadmap | ¹û¶³Ó°Ôº Therapeutic Innovation Networks - ¹û¶³Ó°Ôº – ¹û¶³Ó°Ôº
-ÌýRegenerative Medicines Case Studies | ¹û¶³Ó°Ôº Therapeutic Innovation Networks - ¹û¶³Ó°Ôº – ¹û¶³Ó°Ôº
-ÌýSmall Molecules Translation Roadmap | ¹û¶³Ó°Ôº Therapeutic Innovation Networks - ¹û¶³Ó°Ôº – ¹û¶³Ó°Ôº Repurposing | ¹û¶³Ó°Ôº Therapeutic Innovation Networks - ¹û¶³Ó°Ôº – ¹û¶³Ó°ÔºLanding page:Ìý¹û¶³Ó°Ôº Therapeutic Innovations Networks (TINs) | ¹û¶³Ó°Ôº Therapeutic Innovation Networks - ¹û¶³Ó°Ôº – ¹û¶³Ó°Ôº.
TheseÌýresources areÌýoffered by the Therapeutic Innovations Networks (TINs @¹û¶³Ó°Ôº). The TINsÌýis a specific framework embedded in the Translational Research Office (TRO)Ìýand partnered with NIHR Biomedical Research Centres (¹û¶³Ó°ÔºH, Great Ormond Street Hospital, Moorfields eye hospital) for education, training and outreach of early career researchers.
The TRO's main purpose is to support translational research at ¹û¶³Ó°Ôº Translational Research Office | Translational Research Office (TRO) - ¹û¶³Ó°Ôº – ¹û¶³Ó°Ôº.
Webinars:ÌýTIN Webinar Recordings | ¹û¶³Ó°Ôº Therapeutic Innovation Networks - ¹û¶³Ó°Ôº – ¹û¶³Ó°Ôº
- FOCUS on the development pathway and regulations of gene, cell and tissue therapy (ATMPs: advanced therapy medical products)
Advanced therapy medicinal products (ATMPs) are medicines for human use that areÌýeitherÌýa gene therapy medicinal product, a somatic cell therapy medicinal product, orÌýÌýa tissue engineered product. Here you can find informativeÌýmaterial from the UK and EU regulatory agency.
- MHRA (UK):Ìý
- EMA (EU):Ìý, and alsoÌý
More webinars and material on ATMPs from London Advanced Therapies in collaboration with NHS- After the initial registration, search for key words such as 'cell/gene therapy'Ìý
- Ìýseries of talks, case studies and tool kitTalk by Prof Mark Lowdell (¹û¶³Ó°Ôº) on advancing ATMPs from academia to industryÌý
-ÌýÌý
Ìý
- FOCUS on the development pathway and regulations of small molecules and devices
This presentationÌýwas made by Deloitte and published by gov.uk* (2016) as aÌýguide to navigating the innovation pathway in England. It includes development pathways for pharmaceuticals and medical technologies.ÌýÌý(*The document is pre-Brexit, therefore some links are not anymore up to date or available. Check with the TRO/TRM if you have specific questions). -Ìý.
Oxford also offers some interesting webinars freely available:
Small molecule:Ìý. The University of Oxford offers a series of videos to discuss the experience of innovators from pharma (Bayers, Astra Zeneca), but also regulators. Click here you hear about target validation, regulation, commercialisation and investment opportunities.Ìý
Devices:Ìý. The development of a device follows different regulations compared to a biologic.ÌýIt is also good practice to have an idea of the category to which the device belongs.ÌýThe online tool RegMetrics is a digital platform to support health technology innovators in navigating the medical device regulations. The technology was initially developed by the Natural Interaction Lab () at the University of Oxford, as a solution for a need that was observed within the community of innovators.Ìý- IP (Intellectual property) - ¹û¶³Ó°Ôº resources
¹û¶³Ó°ÔºB (tech transfer office) follows any development for intellectual property establishment at ¹û¶³Ó°Ôº.
- General policy:Ìý¹û¶³Ó°Ôº Intellectual Property (IP) Policy | Innovation & Enterprise - ¹û¶³Ó°Ôº – ¹û¶³Ó°Ôº
-ÌýCommercialisation of an IP and revenue sharing policy at ¹û¶³Ó°Ôº:Ìý¹û¶³Ó°Ôº Revenue Sharing Policy | Innovation & Enterprise - ¹û¶³Ó°Ôº – ¹û¶³Ó°Ôº
-ÌýNon-patentable IP:ÌýFor any enquires see UCB Q&AÌýÌýor contact one of the Business Managers:Ìý,Ìý.Ìý
- PPI (Patient and Public involvement)
Evidence of involving patients and the public in the planning, design, management and/or dissemination of research is increasingly a requirement of major funding bodies in the UK. ¹û¶³Ó°ÔºÌýprovideS an online PPI helpdesk that researchers can contact PatienceÌýfor advice on PPI. The helpdesk can be contacted onÌýppihelpdesk@ucl.ac.uk.
Other resources are:
- The JROÌýAbout |ÌýAbout | Joint Research Office - ¹û¶³Ó°Ôº – ¹û¶³Ó°Ôº
- The NIHR ¹û¶³Ó°ÔºH Biomedical Research Centre runs a programme of regular workshops for researchers at ¹û¶³Ó°Ôº Partner organisations on patient and public involvement (PPI) in research.Ìý
-Ìý
- Charities